BP793

Budesonide

British Pharmacopoeia (BP) Reference Standard

• Synonim(y): 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
• Wzór empiryczny (zapis Hilla): C₂₅H₃₄O₆
• Numer CAS: 51333-22-3
• Masa cząsteczkowa: 430.53
• UNSPSC Code: 41116107
• NACRES: NA.24
• MDL number: MFCD00083259

Właściwości

• grade: pharmaceutical primary standard
• API family: budesonide
• form: solid
• shelf life: limited shelf life, expiry date on the label
• manufacturer/tradename: BP
• application(s): pharmaceutical; pharmaceutical small molecule
• format: neat
• SMILES string: [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
• InChI: 1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
• InChI key: VOVIALXJUBGFJZ-KWVAZRHASA-N
• Gene Information: human ... NR3C1(2908)

Opis

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Budesonide BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Budesonide Aqueous Nasal Spray

Budesonide Inhalation Powder, pre-metered

Budesonide Inhalation Powder

Budesonide Pressurised Inhalation

Budesonide Nebuliser Suspension

Biochem/physiol Actions

Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.

Second generation glucocorticoid with low systemic absorption; anti-inflammatory agent; inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein.

Packaging

Unit quantity: 110 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Other Notes

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS08,GHS07
• signalword: Danger
• hcodes: H302,H317,H361d,H372,H412
• pcodes: P202 - P273 - P280 - P301 + P312 - P302 + P352 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
• target_organs: Adrenal gland
• Klasa składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable